Master study for relapsed or hard-to-treat acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial is for people with acute myeloid leukemia (AML) that has come back (relapsed) or is not responding to treatment (refractory). It tests different new treatments to find which ones work best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of acute myeloid leukemia (AML).
- Your leukemia must have come back after treatment, not responded, or progressed (including signs of minimal residual disease).
- You or your legal guardian must be willing to sign a consent form to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy called CCTx-001 for people with acute myeloid leukemia that has not responded to standard treatments or has come back. The treatment involves collecting your own immune cells, engineering them, and giving them back to attack the leukemia.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
This study looks at individual leukemia cells to better understand why the disease comes back or doesn't respond to treatment. It may help doctors find better ways to treat people with this condition.
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.